Harvard Business Review

JULY 8, 2016

China has not been a huge technology innovator, despite being the world’s second-largest investor in R&D , but Chinese businesses have found ways to use innovations in processes, business models, and customer experience to their disruptive advantage. This presents Western companies with a fresh challenge.

Business Model 10

Business Model Innovation Company Apparel 10

Coaching Tip

MARCH 15, 2011

In a capitalist democracy, government should not be involved with what we in the private sector do, which is managing time to manage money. All it takes is the desire to be innovative and creative in tackling a problem. In tough times like these, the seeming allure of the cosseting “Nanny-State” can indeed appear seductive.

Pharmaceuticals 84

Pharmaceuticals Creativity Long-term Power 84

Harvard Business Review

JANUARY 27, 2016

Much fanfare has been paid to the term “disruptive innovation” over the past few years. Christensen has even re-entered the fold clarifying what he means when he uses the term. Disruptive innovations are: Cheaper (from a customer perspective). Is 23andMe potentially disruptive to pharmaceutical companies?

Disruptive Innovation 8

Disruptive Innovation Innovation Short-term Long-term 8

Harvard Business Review

JUNE 29, 2015

And a recent working paper out of the Dusseldorf Institute for Competition Economics ( DICE ), a think tank of sorts, focuses on the latter by exploring whether leveraged buyouts (LBOs) make firms more innovative. PE investors don’t typically invest in firms known for innovation.

LBO 8

LBO Innovation Sample Short-term 8

Harvard Business Review

MARCH 14, 2017

For industries that depend on innovation, sustaining it is a constant challenge. These two actions cost almost nothing compared to vast sums often spent — and arguably, often wasted — on efforts to foster innovation. Yet they have already generated tens of millions of dollars in value for Roivant.

Innovation 9

Innovation Company Incentives Industry 9

Harvard Business Review

APRIL 2, 2018

There is an abundance of high-quality comparative effectiveness data for pharmaceuticals, largely because of the drug approval process, but there’s less data on the value of other expensive investments into health, such as doctor visits and hospitalizations. (For

Health Care 8

Health Care Insurance Pharmaceuticals Incentives 8

Harvard Business Review

DECEMBER 16, 2014

Obama reportedly felt the situation called for someone who could set priorities and help government agencies and private sector organizations of all kinds to collaborate and innovate. Top-down management simply will not get the innovation part of the job done.

Management 9

Management Health Care NGO Crisis Management 9

Harvard Business Review

DECEMBER 14, 2017

Some of the nation’s most innovative, high-performing non-profit health care organizations use this formula. This tends to focus doctors, nurses, and other health professionals on the value of what they do — finding the most cost-effective approach to managing their patients’ problems.

Health Care 8

Health Care System Insurance Pharmaceuticals 8

Harvard Business Review

AUGUST 14, 2018

The term “digital firms” refers to those companies that from their inception have focused on digital services enabled by the internet and related technologies, including mobile. poor management of relations with Chinese regulators and the government. failure to manage relations effectively with local business partners.

Competitive Advantage 11

Competitive Advantage Business Model Technology Marketing 11

Harvard Business Review

SEPTEMBER 26, 2011

The stock market is short-term-oriented. Stock-based incentive compensation aligns the self-interest of management with shareholders, and a performance-based pay system increases employee motivation. In my experience, these beliefs have led managers and boards to take actions that have had unintended, destructive consequences.

CEO 15

CEO Short-term Long-term Restructuring 15

Harvard Business Review

JUNE 27, 2012

Paul is an old friend who, until his recent retirement, worked as a senior scientist at a pharmaceutical company, where he managed a group of innovative researchers. Some good scientists left the company, and others lost their innovative spark. If this homogenization had worked, it might well have spelled disaster.

COO 11

COO Short-term Pharmaceuticals Innovation 11

Harvard Business Review

JANUARY 10, 2014

I see a rise in business combinations of all kinds — not just M&A, but also partnerships, alliances, joint ventures, and consortia that stop short of being full mergers. But it will be important for managers to know when to use each of these types of deals. And therein lay serious challenges for managers.

Restructuring 8

Restructuring Trends Long-term Short-term 8

Harvard Business Review

JUNE 20, 2017

For organizations seeking to become more adaptive and innovative, culture change is often the most challenging part of the transformation. Innovation demands new behaviors from leaders and employees that are often antithetical to corporate cultures, which are historically focused on operational excellence and efficiency.

Company 15

Company Agility Innovation Learning-by-Doing 15

Harvard Business Review

SEPTEMBER 5, 2016

Cigna is the first insurance company to get pharmaceutical companies to agree to value pricing based on results for certain cholesterol-lowering drugs. And providers want the flexibility to deliver outcomes in the best, most innovative, and most efficient way possible without being micromanaged by the customer. ” Health care.

Incentives 8

Incentives Health Care Education Insurance 8

Harvard Business Review

SEPTEMBER 10, 2013

A good idea faces so many obstacles en route to market today that it''s a wonder we have any innovative products at all. Effective means of boosting innovation already exist, but not enough companies are making use of them. I''ll describe both, but first let''s look at what''s wrong with some of the traditional sources of innovation.

Venture Capitalist 8

Venture Capitalist Venture Funding Innovation Incentives 8

Harvard Business Review

SEPTEMBER 10, 2013

A good idea faces so many obstacles en route to market today that it’s a wonder we have any innovative products at all. Effective means of boosting innovation already exist, but not enough companies are making use of them. You know those baby sea turtles that get eaten by birds and crabs on their way from the nest to the water?

Venture Capitalist 8

Venture Capitalist Venture Funding Innovation Incentives 8

Harvard Business Review

APRIL 16, 2012

Strategic cash also can be used to finance long-term reinvestment programs in the business—which is especially valuable to companies in capital-intensive industries (e.g., high technology or pharmaceutical) that are investing in projects with uncertain long-range payoffs. Facilitate Investments. Arguments Against Strategic Cash.

Company 13

Company Cost of Capital Finance Long-term 13

Harvard Business Review

JUNE 23, 2016

A global pharmaceutical company was about to lose the strategic advantage of several blockbuster drugs coming off patent. However, equally rare is tapping into the minds of a group of imaginative, open-minded employees and managers to scope out potential strategic opportunities. paul Garbett for HBR.

Leadership 10

Leadership Diversity Committee Long-term 10

Harvard Business Review

FEBRUARY 4, 2013

In short, change would happen, but at a dangerously slow pace. Our research with members of the global C-suite, and with leading sustainability and innovation experts, has identified seven vectors of breakthrough change. Perhaps surprisingly, two leading examples come from pharmaceutical companies. Breakthrough Science.

EPS 8

EPS Innovation CEO Pharmaceuticals 8

Harvard Business Review

APRIL 24, 2017

Because the long-term horizon and trade-offs required to develop scalable responses to pandemic threats are exactly the type of problem too big to be solved by any one sector. and the global community can manage them. In short, we must adopt a global “invest now or pay later” economic philosophy. Private sector.

Project 8

Project Disaggregation Globalization Comparison 8

Harvard Business Review

SEPTEMBER 5, 2013

With scarcely any help from management, knowledge workers can increase their productivity by 20%. Yet here is the challenge you face as a senior executive: You cannot manage your knowledge workers in the traditional and intrusive way you might have done with manual workers.

Productivity 8

Productivity Products Peer Review Short-term 8

Harvard Business Review

FEBRUARY 11, 2016

McKesson, the US-based pharmaceutical and health-care giant, benefits from external expertise as a strategic extension of its resources in areas such as business strategy and logistics support. ” Most managers would never dream of treating externals like internals. One of the main problems is decision making. Adapted from.

Agility 8

Agility Organization Resources Fixed Costs 8

Harvard Business Review

SEPTEMBER 20, 2013

Content Innovation. Very importantly, they were able to avoid costly technology and implementation programs that would have surely fell short of usage and revenue expectations. The innovation consulting firm Innosight often refers to “$50 million in 5 years” as a reasonable target for a brand new business. Do you decide to stop?

Execution 8

Execution Metrics Content Christensen 8

Harvard Business Review

SEPTEMBER 4, 2015

Innovation is widely regarded as important to long-term business performance. We’ve found that CEOs of big pharmaceutical companies, for example, are more likely to have a background as company lawyers, salespeople, or finance managers, than one in medicine or pharmaceutical R&D.

CEO 8

CEO Innovation Pharmaceuticals Merchandising 8

Harvard Business Review

NOVEMBER 20, 2015

But let’s change what we’re asking: Which has the better potential to scale up and create long term value for customers, owners, investors, and employees? Manage culture by setting expectations appropriately. Manage the arduously long sales cycle. No doubt the tech startup wins the popularity contest hands down.

Supply Chain 8

Supply Chain Collins Golden Handcuff Pharmaceuticals 8

Harvard Business Review

MAY 10, 2013

As noted management expert Geoffrey Moore told me with respect to high-velocity competition, "I''m not sure you ever want to be in the public markets." Such a pattern is well established in the pharmaceutical industry as large established firms partner with smaller biotech firms. So we are left with a quandary.

Venture Capitalist 8

Venture Capitalist Restructuring Competitive Advantage Short-term 8

Harvard Business Review

MARCH 8, 2011

All too soon, however, the demands of managing the near-term business take over. Lafley became the CEO of Procter & Gamble, he saw that the company's current expansion strategy, which had put it in markets as diverse as pharmaceuticals and snack foods, would continue to erode value.

Merchandising 14

Merchandising Budgeting Pharmaceuticals CEO 14

Harvard Business Review

JUNE 24, 2015

The f ive forces framework for strategy may be valid in one arena, blue ocean or open innovation in another, but each approach to strategy tends to be presented or perceived as a panacea. In fact, for many managers, it may be the approach that defines strategy. • Adaptive: Be fast. • Visionary: Be first.

Strategy 8

Strategy Competitive Advantage Environment Execution 8

Harvard Business Review

JULY 20, 2017

The innovation alone is a herculean task, but imagine being that upstart pioneer trying to develop the technology, while at the same time going up against entrenched, powerful competitors with deep industry knowledge, assets, and channels who’ve been around for a hundred years or more. This is an incredible moment for innovation.

Innovation 13

Innovation Productivity Products Venture Capitalist 13

Harvard Business Review

NOVEMBER 3, 2017

The team tasked with overseeing the effort designed an aggressive implementation plan that tied targets to manager compensation. However, beyond the strategic goal of becoming an industry leader in terms of cost structure, there was no “story” for how this effort would complement the business’s broader ambitions.

Execution 14

Execution Strategy Decentralization Short-term 14

Harvard Business Review

MAY 12, 2011

Instead of a pharmaceutical industry, I see a new set of mental and physical discontents, like rates of suspiciously normally "abnormal" mental illnesses and drugs whose lists of "side effects" are longer than the Magna Carta. Gary Hamel , whose Future of Management is about creating the capacity to live better. Better, not just more.

GDP 21

GDP Hamel Industry Construction 21

Harvard Business Review

JUNE 20, 2017

Firms in innovation-driven industries, such as pharmaceuticals and medical devices, have long supported greater standardization across borders, with stronger intellectual property protections and enforcement of regulatory standards. Economic growth would fall to -1.5%

Supply Chain 8

Supply Chain Depreciation Uncertainty Marketing 8

Harvard Business Review

OCTOBER 8, 2013

And because it focuses on acute episodes, REBP acts as a necessary complement to payment and care-delivery models designed to improve prevention and chronic-care management. In short, REBP can serve as a bridge to more comprehensive total-cost-of-care approaches. pharmaceuticals, physical therapy, skilled nursing facility care).

Health Care 8

Health Care Cost Analysis Competitive Advantage 8